• Explore /
  • Poster
  • / Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

Abstract Poster

Authors

null

Maria-Victoria Mateos

University of Salamanca Hospital, Salamanca, Spain

Maria-Victoria Mateos , Andrew Spencer , Ajay K. Nooka , Ludek Pour , Katja C. Weisel , Michele Cavo , Jacob Laubach , Gordon Cook , Shinsuke Iida , Lotfi Benboubker , Saad Zafar Usmani , Sung-Soo Yoon , Nizar J. Bahlis , Christopher Chiu , Jordan Mark Schecter , Kaida Wu , Xiang Qin , David Soong , Meletios A. Dimopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02136134 and NCT02076009

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8033)

DOI

10.1200/JCO.2017.35.15_suppl.8033

Abstract #

8033

Poster Bd #

359

Abstract Disclosures

Similar Posters

First Author: Cyrille Touzeau

First Author: Xavier Leleu

First Author: Pieter Sonneveld

First Author: Nizar J. Bahlis